Voltaren Emulgel gel for external use

Country: Հայաստան

language: անգլերեն

source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

SPC SPC (SPC)
01-07-2020

active_ingredient:

diclofenac (diclofenac diethylamine)

MAH:

GlaxoSmithKline Consumer Healthcare S.A.

ATC_code:

M02AA15

INN:

diclofenac (diclofenac diethylamine)

dosage:

10mg/g

pharmaceutical_form:

gel for external use

units_in_package:

20g, 50g and 100g laminated tube

prescription_type:

OTC

authorization_status:

Registered

authorization_date:

2019-01-09

SPC

                                GSK Consumer Healthcare S.A.,
Switzerland.
Summary of Product Characteristics
Global Labeling
VOLTAREN
Gel
Diclofenac diethylamine 1.16%
SUMMARY OF PRODUCT CHARACTERISTICS
Document status:
FINAL
Release date:
10 Oct 2019
Number of pages:
8
GSK Consumer Healthcare S.A.,
Switzerland.
Summary of Product Characteristics
TABLE OF CONTENTS
1
NAME OF THE MEDICINAL PRODUCT
.......................................................................
3
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
............................................. 3
3
PHARMACEUTICAL FORM
............................................................................................
3
4
CLINICAL PARTICULARS
..............................................................................................
3
4.1
Pharmacotherapeutic group
.....................................................................................
3
4.2
Posology and method of administration
.................................................................. 4
4.3
Contraindications
.....................................................................................................
4
4.4
Special warnings and precautions for use
................................................................ 5
4.5
Interaction with other medicinal products and other forms of
interaction .............. 5
4.6
Pregnancy and lactation
...........................................................................................
5
4.7
Effects on ability to drive and use machines
........................................................... 5
4.8
Undesirable effects
..................................................................................................
6
4.9
Overdose
..................................................................................................................
7
PHARMACOLOGICAL PROPERTIES
...................................................................................
7
4.3
Pharmacodynamic properties
...................................................................................
7
                                
                                read_full_document
                                
                            

documents_in_other_languages

PIL PIL ռուսերեն 01-07-2020